Related Experiment Videos
Topical cyclosporine in vernal keratoconjunctivitis
1Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Ophthalmology
|November 1, 1991
Summary
Topical 2% cyclosporine effectively treated vernal keratoconjunctivitis (VKC) symptoms and signs. This safe and effective short-term treatment showed no adverse effects in pediatric patients.
Area of Science:
- Ophthalmology
- Immunology
Background:
- Vernal keratoconjunctivitis (VKC) is a chronic allergic eye condition.
- VKC affects children and young adults, causing significant discomfort and visual impairment.
Purpose of the Study:
- To evaluate the efficacy and safety of topical 2% cyclosporine in treating VKC.
- To assess the impact of cyclosporine on key clinical signs and symptoms of VKC.
Main Methods:
- A placebo-controlled, double-masked clinical trial was conducted.
- Twenty patients diagnosed with VKC were treated with either 2% cyclosporine or placebo for 6 weeks.
- Symptoms and clinical signs were monitored weekly.
Main Results:
- Cyclosporine treatment led to a statistically significant reduction in conjunctival hyperemia, papillary hypertrophy, punctate keratitis, and Trantas' dots.
- No significant improvements were observed in the placebo group.
- No adverse effects or detectable blood cyclosporine levels were reported.
Conclusions:
- Topical 2% cyclosporine is a safe and effective short-term treatment for pediatric VKC.
- Cyclosporine demonstrates a positive impact on both the clinical signs and symptoms of VKC.